Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Sep 30, 2026, 5:08 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 308 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: moxifloxacin Clear all
Completed Phase 1 Interventional

A Thorough ECG Study in Subjects With Acne Vulgaris Treated With SB204

NCT02581072
View directory record Official record
Conditions
Acne Vulgaris
Interventions
SB204 4%, SB204 8% or 12%, Vehicle
Drug
Lead sponsor
Novan, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
West Bend, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 19, 2018 · Synced Sep 30, 2026, 5:08 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate Pharmacokinetics, Pharmacodynamics and Tissue Concentrations of Epelsiban

NCT02213029
View directory record Official record
Conditions
Embryo Transfer
Interventions
Epelsiban, Placebo, Oxytocin, Ortho-Cylcen (21)® tablet
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 35 Years · Female only
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
2
States / cities
Glendale, California • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 8, 2017 · Synced Sep 30, 2026, 5:08 PM EDT
Completed Phase 3 Interventional Results available

BAY12-8039: 5 Days for Sinusitis vs Placebo

NCT00492024
View directory record Official record
Conditions
Sinusitis
Interventions
Moxifloxacin (Avelox, BAY12-8039), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
374 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
51
States / cities
Birmingham, Alabama • Northport, Alabama • Jonesboro, Arkansas + 45 more
Source: ClinicalTrials.gov public record
Updated Nov 26, 2013 · Synced Sep 30, 2026, 5:08 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of ALKS 5461 on QT Intervals in Healthy Volunteers

NCT02479308
View directory record Official record
Conditions
Healthy
Interventions
Moxifloxacin, ALKS 5461, Placebo
Drug
Lead sponsor
Alkermes, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
129 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Nov 23, 2015 · Synced Sep 30, 2026, 5:08 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Define the ECG Effects of Lixivaptan Compared to Placebo and Moxifloxacin in Healthy Adult Men and Women: A Thorough ECG Study

NCT00675701
View directory record Official record
Conditions
Healthy
Interventions
placebo, lixivaptan, moxifloxacin
Drug
Lead sponsor
CardioKine Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
298 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jun 21, 2011 · Synced Sep 30, 2026, 5:08 PM EDT
Completed No phase listed Observational

Antibiotic Resistant Patterns of Conjunctival and Nasophayngeal Flora After Repeated Exposure to Topical Antibiotics

NCT00831961
View directory record Official record
Conditions
Age-related Macular Degeneration
Interventions
Conjunctival and nasopharyngeal bacteria cultures
Procedure
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 9, 2015 · Synced Sep 30, 2026, 5:08 PM EDT
Completed Phase 4 Interventional Results available

Moxifloxacin vs. Polytrim for Conjunctivitis

NCT00581542
View directory record Official record
Conditions
Conjunctivitis
Interventions
moxifloxacin, polytrim
Drug
Lead sponsor
University of Rochester
Other
Eligibility
1 Year to 18 Years
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jan 18, 2016 · Synced Sep 30, 2026, 5:08 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Effect of Aficamten Administration on QT/QTc Interval

NCT05924815
View directory record Official record
Conditions
Healthy Participants
Interventions
Aficamten, Aficamten-matching Placebo, Moxifloxacin
Drug
Lead sponsor
Cytokinetics
Industry
Eligibility
18 Years to 45 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Dec 19, 2023 · Synced Sep 30, 2026, 5:08 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Guanfacine Immediate-release Electrocardiogram Results (QTc) Study

NCT00672984
View directory record Official record
Conditions
Healthy Volunteers
Interventions
immediate release guanfacine hydrochloride, moxifloxacin, Placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 45 Years
Enrollment
83 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Jun 14, 2021 · Synced Sep 30, 2026, 5:08 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluate Effects of Meropenem-Vaborbactam on QT/QTc in Healthy Volunteers

NCT03564158
View directory record Official record
Conditions
Healthy
Interventions
meropenem-vaborbactam, Placebo, Moxifloxacin
Drug
Lead sponsor
Rempex (a wholly owned subsidiary of Melinta Therapeutics, Inc.)
Industry
Eligibility
18 Years to 55 Years
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 10, 2019 · Synced Sep 30, 2026, 5:08 PM EDT
Completed Phase 3 Interventional

AMS VS MOXI Ketek vs Avelox in AMS

NCT00537563
View directory record Official record
Conditions
Maxillary Sinusitis
Interventions
Telithromycin
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
351 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 17, 2012 · Synced Sep 30, 2026, 5:08 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of LY2484595 on the Electrical Activity of the Heart

NCT01537887
View directory record Official record
Conditions
Healthy Volunteers
Interventions
LY2484595, Placebo, Moxifloxacin
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
2
States / cities
Daytona Beach, Florida • Evansville, Indiana
Source: ClinicalTrials.gov public record
Updated Mar 7, 2019 · Synced Sep 30, 2026, 5:08 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of TAK-279 in Healthy Adults on the Effect on ECG Measurements

NCT06258265
View directory record Official record
Conditions
Healthy Volunteers
Interventions
TAK-279, TAK-279 Placebo, Moxifloxacin, Moxifloxacin Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 55 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Jul 11, 2024 · Synced Sep 30, 2026, 5:08 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Two-Part Phase 1 Study to Investigate the Safety and Tolerability of Supratherapeutic Dose of Zanubrutinib and Effect of Zanubrutinib on Cardiac Repolarization in Healthy Subjects

NCT03432884
View directory record Official record
Conditions
Healthy Volunteers
Interventions
BGB-3111, Placebo, Moxifloxacin
Drug
Lead sponsor
BeiGene
Industry
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Secaucus, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 24, 2020 · Synced Sep 30, 2026, 5:08 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of LY2216684 in Healthy Females

NCT01373931
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
LY2216684, Ortho Cyclen, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 23, 2018 · Synced Sep 30, 2026, 5:08 PM EDT
Terminated No phase listed Observational

Collagen Crosslinking With Ultraviolet-A in Asymmetric Corneas

NCT01024322
View directory record Official record
Conditions
Keratoconus, Ectasia, Degeneration
Interventions
Ciprofloxicine or Vigamox or other., Nonsteroidal (Acular, Voltaren Xibrom, etc), Steroid (FML, Pred Forte, Flarex, etc.)
Drug
Lead sponsor
Cxlusa
Industry
Eligibility
8 Years and older
Enrollment
1,189 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
3
States / cities
Miami, Florida • Rockville, Maryland • Fairfax, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 11, 2018 · Synced Sep 30, 2026, 5:08 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A TQT Study to Evaluate the Electrocardiographic Effects of Carbidopa in Healthy Subjects

NCT06161220
View directory record Official record
Conditions
Cardiac Repolarization in Healthy Subjects
Interventions
Carbidopa capsule, Moxifloxacin Tablets, USP, Placebo
Drug
Lead sponsor
Impax Laboratories, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Dilworth, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 5, 2024 · Synced Sep 30, 2026, 5:08 PM EDT
Terminated No phase listed Observational

Collagen Crosslinking With Ultraviolet-A in Asymmetric Corneas (2)

NCT01097447
View directory record Official record
Conditions
Keratoconus, Ectasia, Degeneration
Interventions
Not listed
Lead sponsor
Cxlusa
Industry
Eligibility
8 Years and older
Enrollment
2,619 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
5
States / cities
San Diego, California • Littleton, Colorado • Hoffman Estates, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 11, 2018 · Synced Sep 30, 2026, 5:08 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

AG200-15 Transdermal Contraceptive Delivery System (TCDS) of Levonorgestrel and Ethinyl Estradiol

NCT01243580
View directory record Official record
Conditions
Healthy
Interventions
Ortho-Cyclen, AG200-15
Drug
Lead sponsor
Agile Therapeutics
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jan 23, 2018 · Synced Sep 30, 2026, 5:08 PM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

Effectiveness Study of Zymar Versus Vigamox for Preoperative Sterilization of the Ocular Surface After Loading Dose

NCT00347828
View directory record Official record
Conditions
Eye Infection, Infection
Interventions
Moxifloxacin ophthalmic solution 0.5%, Gatifloxacin ophthalmic solution 0.3%
Drug
Lead sponsor
Ophthalmic Consultants of Boston
Other
Eligibility
25 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 4, 2006 · Synced Sep 30, 2026, 5:08 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Dropless Pars Plana Vitrectomy Study

NCT05331664
View directory record Official record
Conditions
Rhegmatogenous Retinal Detachment
Interventions
Pars plana vitrectomy, Triamcinolone Acetonide 40mg/mL, Moxifloxacin 0.5% or Polymyxin/Trimethoprim if patient is allergic to moxifloxacin, Prednisolone 1%, Atropine 1%
Procedure · Drug
Lead sponsor
Massachusetts Eye and Ear Infirmary
Other
Eligibility
40 Years and older
Enrollment
168 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Sep 30, 2026, 5:08 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Effects of Tramadol Hydrochloride on Cardiac Repolarization in Healthy Participants

NCT02307864
View directory record Official record
Conditions
Healthy
Interventions
Tramadol HCl, Moxifloxacin 400 mg, Tramadol HCl Placebo, Moxifloxacin Placebo
Drug
Lead sponsor
Janssen Scientific Affairs, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
68 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Aug 29, 2018 · Synced Sep 30, 2026, 5:08 PM EDT
Completed Phase 3 Interventional

Intermittent Moxifloxacin Therapy For The Prevention Of Acute Exacerbations In Patients With Chronic Bronchitis

NCT00473460
View directory record Official record
Conditions
Lung Diseases, Bronchitis, Chronic
Interventions
Avelox (Moxifloxacin, BAY12-8039), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
45 Years to 90 Years
Enrollment
1,404 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
11
States / cities
Tucson, Arizona • Long Beach, California • Los Angeles, California + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2014 · Synced Sep 30, 2026, 5:08 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Study of AzaSite Versus Vigamox Concentrations in the Conjunctiva and Aqueous Humor in Subjects Undergoing Routine Cataract Surgery

NCT00575380
View directory record Official record
Conditions
Bacterial Infections, Eye Infections, Cataract Extraction
Interventions
AzaSite Eye Drops, Vigamox Eye Drops
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
21 Years and older
Enrollment
116 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2007
U.S. locations
13
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Mission Hills, California + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2011 · Synced Sep 30, 2026, 5:08 PM EDT